Blog
Alpha-2-Macroglobulin (A2M) Breakthrough Arthritis Treatment
A2M halts the progression of osteoarthritis at the molecular level by inactivating the chemicals that cause the joints to bre...
The Impact of Proteins on Joints
One of the most common causes of joint pain is the development of unbalanced proteins within the joints that accumulate, crea...
Putting the Fight Back in Fighters with A2M
A2M has the ability to prevent cartilage breakdown and restore tissue and function in joints affected by the degenerative eff...
Joint Pain in Young Adults
Review the following information about the joint-soothing properties of the natural protein A2M to gain a better understandin...
Non-Surgical Treatment for Musculoskeletal Pain
A2M injections is the answer for people who want to manage their pain without surgery....
Take Control of Chronic Back Pain with A2M Injections
Back pain is one of the most common conditions that lead Americans to seek help from their doctor. Often, it’s difficult to p...
Royce Gracie & A2M Therapy
Just had A2M therapy with the founder of Cytonics, Dr. Gaetano Scuderi. No pain at all and amazing results! Dr. Scuderi (orth...
Motorcycle accident launches Jupiter biotech enterprise
During Scuderi’s medical leave from surgery, he spent time as a professor at the Stanford University School of Medicine — a s...
DR. SCUDERI’S INCREDIBLE JOURNEY FROM CRASH VICTIM TO VISIONARY
ccelerating his Ducati up the ramp onto I-95 on a bright sunny day in 2005, fellowship-trained spine surgeon Guy Scuderi coul...
Researchers create “truth serum” to explain knee pain
Researchers at the School of Medicine identified a biomarker for pain associated with cartilage injury in...
Press Releases
Cytonics Corporation and Astaria Global Announce an Exclusive Licensing Agreement
October 9, 2019Jupiter, FL: Cytonics Corporation, a biotechnology company focused on developing therapies for osteoarthritis ...
Cytonics Receives Feedback from the FDA on Pre-Clinical and Phase 1 Trial Designs for Cyt-108
NOVEMBER 2, 2018 Jupiter, FL: Cytonics Corporation received feedback on the pre-clinical and clinical trial designs for their...
Cytonics Raises $794,000 to Fund Pre-Clinical Large Animal Studies for the Lead Recombinant Drug Candidate Cyt-108
SEPTEMBER 30, 2018 Jupiter, FL: Cytonics Corporation has completed a bridge round of financing to fund the company’s pre-clin...
Cytonics Has Expressed and Purified an Enzymatically Active Recombinant Alpha-2-Macroglobulin Variant (Cyt-108)
JULY 10, 2018 Jupiter, FL: Cytonics Corporation has developed a methodology for expressing and purifying recombinant A2M vari...
Cytonics Announces Issuance of PCT Patent for the APIC-PRP System and a Method of Producing Recombinant Alpha-2-Macroglobulin (A2M) Variants
MARCH 31, 2018 Jupiter, FL: Cytonics Corporation, a biotechnology company focused on the development of biologic therapies fo...
Cytonics Announces Issuance of US Patent for the APIC-PRP System and a Method of Producing Recombinant Alpha-2-Macroglobulin (A2M) Variants
NOVEMBER 22, 2016 Jupiter, FL: Cytonics Corporation, a biotechnology company focused on the development of biologic therapies...
Cytonics Announces Issuance of UK Patent for the APIC-PRP System
SEPTEMBER 21, 2016 Jupiter, FL: Cytonics Corporation, a biotechnology company focused on the development of biologic therapie...
Cytonics Announces Issuance of US Patent for a Method of Treatment of Chronic Wounds Using Alpha-2-Macroglobulin (A2M) from Whole Blood or a Recombinant Variant of A2M
May 31, 2016 Jupiter, FL: Cytonics Corporation, a biotechnology company focused on the development of biologic therapies for ...
Cytonics Announces Issuance of UK Patent for an Alpha-2-Macroglobulin (A2M) Preparation from a Biological Sample
MARCH 4, 2015 Jupiter, FL: Cytonics Corporation, a biotechnology company focused on the development of biologic therapies for...
Cytonics’ APIC™ Procedure Highlighted by Local News Station
WSVN — Knee pain is more common because as we age, we’re staying more active. A new technology is helping some people avoid s...
Cytonics Announces FDA Approval of an Investigational New Drug Application for the APIC Cell-Free System
July 22, 2014 08:00 ETCytonics Announces FDA Approval of an Investigational New Drug Application for the APIC Cell-Free Syste...
Cytonics’ Breakthrough Research is Validated by Independent Study on A2M
July 17, 2014, 09:59 ETCytonics' Breakthrough Research Is Validated by Independent Study on A2MJUPITER, FL--(Marketwired - Ju...
Cytonics to Introduce the FACT™ Diagnostic for Joint and Spine Related Pain at the 2013 Workers Compensation Conference in Orlando, FL
Cytonics to Introduce the FACT™ Diagnostic for Joint and Spine-Related Pain at the 2013 Workers Compensation Conference in O...
Cytonics Awarded Phase 2 NIH SBIR Grant
Cytonics Awarded Phase II NIH SBIR GrantJupiter, FL, November 14, 2012:Cytonics Corporation, a biotechnology company focused ...
Cytonics Receives Notice of Allowance for Patent Related to FACT™ Diagnostic for Back and Joint Pain
Cytonics Announces FDA Approval of an Investigational New Drug Application for the APIC Cell-Free System...
Peer Reviewed Publications
Finding the Replacement for HA Injections in the Knee
Orthopedics This Week -Volume 10, Issue 24...
Arthritis and Rheumatology – July 2014
Identification of α2 -Macroglobulin as a Master Inhibitor of Cartilage-Degrading Factors That Attenuates the Progression of P...
The Spine Journal – April 2013
The Spine Journal - April 2013Does the presence of the fibronectin-aggrecan complex predict outcomes from lumbar discectomy f...
PM&R Journal – April 2013
PM&R Journal - April 2013Does a Fibronectin and Aggrecan Complex Play A Role In Painful Vertebral Disks?...
Journal of Bone & Joint Surgery – December 2012
Journal of Bone & Joint Surgery – December 2012Platelet Rich Plasma Increases Matrix Metalloproteinases in Cultures of Hu...
Orthopedic surgeon set bones, cleaned wounds, did amputations
For four days and nights, Stanford orthopedic surgeon Gaetano Scuderi, MD, fixed fractured and crushed limbs, cleaned decayin...